List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. Development of the VirtualTAVR system for diagnostics and preventative strategies

    SBC: Dura LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Since the first procedure in there has been an explosive growth in transcatheter aortic valve replacement TAVR Up to date more than TAVR had been performed worldwide Despite the increased global experience with TAVR severe adverse events associated with TAVR have been extensively documented including annulus rupture coronary occlusion para ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: LIPELLA PHARMACEUTICALS, INC.            Topic: NIDDK

    DESCRIPTION provided by applicant Lipella Pharmaceuticals Inc Pittsburgh PA is a clinical stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions Lipella is submitting a research proposal to the Small Business Technology Transfer program titled andquot Developing Intravesical Liposomes for Interstitial Cystitisandquot The project proposes to e ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Measurement of Beta Cell Death in Diabetes

    SBC: L2 DIAGNOSTICS, LLC            Topic: 200

    DESCRIPTION provided by applicant All forms of diabetes are characterized by the death of insulin producing cells In Type diabetes T D this leads to the reliance on exogenous insulin for survival Death of cells is silent it cannot be detected in vivo until it has progressed to such an extent that metabolic function is impaired The loss of cells has only been assessed by functiona ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Broad-spectrum, orally-bioavailable beta-lactamase inhibitors

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: R

    DESCRIPTION provided by applicant Broad spectrum orally bioavailable lactam antibiotics play a critical role in the management of human infectious diseases both in the hospital and community settings facilitating exit from the ICU and treatment in the general ward early discharge and or prevention of hospitalization The rapid spread of lactamase driven resistance in Enterobacteriaceae ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. TN-LAMP-vax: a Multi-Valent Tree Nut Allergy Immunotherapy

    SBC: Immunomic Therapeutics, Inc.            Topic: R

    DESCRIPTION provided by applicant Extreme reactions to food results in over incidents of anaphylaxis and between deaths in the US each year Allergies to tree nuts TN such as almond cashew hazelnut and walnut are collectively the second most common triggers of anaphylaxis behind peanut An estimated million Americans are allergic to TNs with many impacted by exposure to ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Ocular Formulation Development of Innovative Novel Compounds with superior ocular

    SBC: CATALYST, LLC            Topic: N

    DESCRIPTION provided by applicant As anyone who has had an eye injury or even a small foreign object in the eye knows the cornea and surrounding structures are exquisitely sensitive to physical trauma Ocular pain can be agonizing paralyzing and extremely distressing to both the affected person and particularly in the case of pediatric cases family members who may feel powerless to help S ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Enabling technologies for rapid and low cost molecular diagnosticshttps://apps.era.nih.gov/grantfolder/grantfolder/viewGrantFolder.do?businessAreaCode=GM&applID=8930749&folderID=90

    SBC: Atharva LLC (dba Atharva Sciences)            Topic: 172

    DESCRIPTION provided by applicant Molecular techniques including diagnostics that require separation or identification of different sized nucleic acid sequences have remained unchanged over the last several decades and rely primarily on some form of electrophoresis Diagnostics for several human diseases such as those associated with trinucleotide repeat instability exemplified by Fragile X s ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Therapeutic for Invasive Candidiasis

    SBC: Fox Chase Chemical Diversity Center, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Systemic fungal infections are increasingly common especially in immune compromised patients While new antifungal drugs have been developed there is still a high mortality associated with these infections especially those due to Candida albicans other non albicans species NAS This is due to the limited spectrum of the drugs significant side effects as ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Synthetic microparticle malaria vaccine

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant This Phase II project will develop a novel synthetic microparticle vaccine for malaria using the T BT epitopes of the circumsporozoite CS protein of Plasmodium falciparum the causative agent of human malaria There is no approved vaccine for malaria a disease that causes up to million new infections and million deaths each year in the developing wor ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Small Molecule Inhibitor for EBV Latent Infection

    SBC: Vironika, LLC            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this research program is to develop a novel small molecule inhibitor of latent Epstein Barr Virus EBV infection EBV is a ubiquitous gamma herpesvirus that has been classified by the World Health Organization as a human carcinogen Vironika with its consortium partners the Wistar Institute and Fox Chase Chemical Diversity Center Inc will deve ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government